Ligand Pharmaceuticals Inc. (LGND) Announces Successful First-In-Human Trial Results For Glucagon Program
6/16/2014 8:45:09 AM
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligand’s novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Association’s 74th Scientific Sessions meeting underway in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
comments powered by